Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities
PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycoba...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yonsei University College of Medicine
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743193/ https://www.ncbi.nlm.nih.gov/pubmed/23918574 http://dx.doi.org/10.3349/ymj.2013.54.5.1227 |
_version_ | 1782280460809797632 |
---|---|
author | Kim, Seo Yun Lee, Sang-Min Yim, Jae-Joon Yoo, Chul-Gyu Kim, Young Whan Han, Sung Koo Yang, Seok-Chul |
author_facet | Kim, Seo Yun Lee, Sang-Min Yim, Jae-Joon Yoo, Chul-Gyu Kim, Young Whan Han, Sung Koo Yang, Seok-Chul |
author_sort | Kim, Seo Yun |
collection | PubMed |
description | PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycobacterium tuberculosis and with available drug susceptibility tests were reviewed retrospectively. These patients were subsequently assigned to either the comorbidity group (n=78) or non-comorbidity group (n=104) depending on whether they had immunocompromising comorbidities. RESULTS: The mean durations of treatment were 9.9±3.3 months in the comorbidity group and 9.3±3.2 months in the non-comorbidity group (p=0.21). M. tuberculosis culture results converted to negative in most patients with available follow-up cultures at two months after treatment. The successful treatment rates were 94.9% and 98.9% in the comorbidity and non-comorbidity groups, respectively (p=0.30). The most common side effects of anti-TB treatment were skin rash/pruritus (13% in the comorbidity group vs. 11% in the non-comorbidity group, p=0.79), gastro-intestinal problems (14% vs. 9%, p=0.25) and hepatotoxicity (14% vs. 7%, p=0.09). CONCLUSION: The present study shows that the successful treatment rate for TB is high and that immunocompromising comorbidities have no effect on the response to treatment and adverse effects in older TB patients. |
format | Online Article Text |
id | pubmed-3743193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Yonsei University College of Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-37431932013-09-01 Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities Kim, Seo Yun Lee, Sang-Min Yim, Jae-Joon Yoo, Chul-Gyu Kim, Young Whan Han, Sung Koo Yang, Seok-Chul Yonsei Med J Original Article PURPOSE: The aim of this study was to elucidate the effects of immunocompromising comorbidities on treatment response and adverse reactions in older tuberculosis (TB) patients. MATERIALS AND METHODS: The medical records of 182 patients older than 65 years with proven TB by positive culture of Mycobacterium tuberculosis and with available drug susceptibility tests were reviewed retrospectively. These patients were subsequently assigned to either the comorbidity group (n=78) or non-comorbidity group (n=104) depending on whether they had immunocompromising comorbidities. RESULTS: The mean durations of treatment were 9.9±3.3 months in the comorbidity group and 9.3±3.2 months in the non-comorbidity group (p=0.21). M. tuberculosis culture results converted to negative in most patients with available follow-up cultures at two months after treatment. The successful treatment rates were 94.9% and 98.9% in the comorbidity and non-comorbidity groups, respectively (p=0.30). The most common side effects of anti-TB treatment were skin rash/pruritus (13% in the comorbidity group vs. 11% in the non-comorbidity group, p=0.79), gastro-intestinal problems (14% vs. 9%, p=0.25) and hepatotoxicity (14% vs. 7%, p=0.09). CONCLUSION: The present study shows that the successful treatment rate for TB is high and that immunocompromising comorbidities have no effect on the response to treatment and adverse effects in older TB patients. Yonsei University College of Medicine 2013-09-01 2013-07-23 /pmc/articles/PMC3743193/ /pubmed/23918574 http://dx.doi.org/10.3349/ymj.2013.54.5.1227 Text en © Copyright: Yonsei University College of Medicine 2013 http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Seo Yun Lee, Sang-Min Yim, Jae-Joon Yoo, Chul-Gyu Kim, Young Whan Han, Sung Koo Yang, Seok-Chul Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities |
title | Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities |
title_full | Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities |
title_fullStr | Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities |
title_full_unstemmed | Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities |
title_short | Treatment Response and Adverse Reactions in Older Tuberculosis Patients with Immunocompromising Comorbidities |
title_sort | treatment response and adverse reactions in older tuberculosis patients with immunocompromising comorbidities |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743193/ https://www.ncbi.nlm.nih.gov/pubmed/23918574 http://dx.doi.org/10.3349/ymj.2013.54.5.1227 |
work_keys_str_mv | AT kimseoyun treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities AT leesangmin treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities AT yimjaejoon treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities AT yoochulgyu treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities AT kimyoungwhan treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities AT hansungkoo treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities AT yangseokchul treatmentresponseandadversereactionsinoldertuberculosispatientswithimmunocompromisingcomorbidities |